Skip to main content
Premium Trial:

Request an Annual Quote

LexaGene Completes C$5.8M Bought Deal Financing

This article has been updated to correctly reflect the price of the bought deal financing in Canadian dollars. 

NEW YORK (GenomeWeb) – LexaGene announced today that it has closed its previously announced bought deal financing, raising gross proceeds of about C$5.8 million ($4.4 million)

The firm, which first announced the offering last month, said it sold about 5.8 million units of stock at an offering price of $1.00 per unit. Each unit consisted of one common share and one-half of one common share purchase warrant, with each warrant entitling the holder to acquire one share at a price of $1.30 per common share until July 11, 2021.

A syndicate of underwriters led by Canaccord Genuity and including Echelon Wealth Partners conducted the offering.

LexaGene, which trades on the Toronto Stock Exchange, said that it will use the proceeds to accelerate the commercialization and deployment of the firm's microfluidic technology and for working capital purposes.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.